Significantly more children get health insurance coverage after increases in federal matching funds to states for Medicaid and the Children's Health Insurance Program (CHIP), according to new research from the University of Michigan. The research, published in the journal Health Affairs, showed...
Palatin Technologies, Inc. (NYSE Amex: PTN) announced that enrollment of patients has commenced in Palatin's Phase 2b clinical trial evaluating the efficacy and safety of bremelanotide (previously called PT-141), an on-demand, first-in-class melanocortin agonist being developed for the treatment...
Ritter Pharmaceuticals, Inc. (Ritter), a pharmaceutical company with a focus on digestive diseases, announced today that clinical investigators have enrolled the first patient in its randomized, double-blind, placebo-controlled Phase 2 study of RP-G28 in patients with symptoms associated with...
Biomet, Inc., a global leader in the manufacture of orthopedic and biotechnology products, announced recently that its subsidiary, Biomet Biologics, LLC, has completed the required 230 subject enrollment for its Recover® Kit clinical trial. This clinical trial studies the use of the Recover®...
Inovio Pharmaceuticals, Inc. (NYSE Amex: INO), a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced the Phase I clinical study assessing Inovio's PENNVAX™-B DNA vaccine delivered using its proprietary electroporation technology in...
Boston Scientific Corporation (NYSE: BSX) has announced the start of patient enrollment in the EVOLVE clinical trial, which is designed to assess the safety and performance of its fourth-generation SYNERGY™ Coronary Stent. The first patient was enrolled by Ian Meredith, M.B.B.S., Ph.D...
Ten million Americans are covered by Health Savings Account (HSA)-eligible insurance plans, an increase of 25 percent since last year, a new census released today by America's Health Insurance Plans (AHIP) finds. Health Savings Accounts were authorized starting in January 2004. Since then...
Artisan Pharma, Inc., a private biopharmaceutical company dedicated to bringing best-in-class critical care therapeutics to patients, announced the completion of patient enrollment in its Phase 2b study of ART-123 (Recomodulin® - recombinant human thrombomodulin) in sepsis patients with...
Impax Pharmaceuticals, the brand products division of Impax Laboratories, Inc. (NASDAQ: IPXL), today announced that it has completed enrollment of its APEX-PD trial. APEX-PD is a multinational Phase III trial of its late-stage drug candidate IPX066 in subjects with early Parkinson's disease...
Impax Pharmaceuticals, the brand products division of Impax Laboratories, Inc. (NASDAQ: IPXL), today announced that it has completed enrollment of its APEX-PD trial. APEX-PD is a multinational Phase III trial of its late-stage drug candidate IPX066 in subjects with early Parkinson's disease...
Impax Pharmaceuticals, the brand products division of Impax Laboratories, Inc. (NASDAQ: IPXL), today announced that it has completed enrollment of its APEX-PD trial. APEX-PD is a multinational Phase III trial of its late-stage drug candidate IPX066 in subjects with early Parkinson's disease...
Boston Scientific Corporation (NYSE: BSX) announced the completion of patient enrollment in the Small Vessel and Long Lesion trials of its PLATINUM clinical program. The trials are designed to compare the platinum chromium PROMUS® Element™ Everolimus-Eluting Stent System to matched historical...
BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) announced that it has achieved its protocol specified objective of enrolling 100 late-stage patients (Stage IIB to IVA) in its pivotal study for forodesine in the treatment of cutaneous T-cell lymphoma (CTCL). Top-line data is expected in the second...
D-Pharm Ltd (TASE: DPRM) announced enrollment of patients with acute ischemic stroke into its Phase III clinical study of DP-b99 (MACSI). The first patient has been enrolled at the Wolfson Medical Center, Israel. The MACSI trial involves numerous medical centers in the US, Canada, Europe...
D-Pharm Ltd (TASE: DPRM) announced enrollment of patients with acute ischemic stroke into its Phase III clinical study of DP-b99 (MACSI). The first patient has been enrolled at the Wolfson Medical Center, Israel. The MACSI trial involves numerous medical centers in the US, Canada, Europe...
POZEN Inc. (NASDAQ: POZN) announced the start of enrollment for the phase 3 studies for PA32540. PA32540 is a fixed-dose combination of 325 mg of enteric coated aspirin and 40 mg of immediate release omeprazole, under investigation for use in the secondary prevention of heart attacks and strokes...